Published in J Clin Oncol on January 01, 2001
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol (2014) 1.70
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer (2011) 1.17
Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. BMC Cancer (2008) 1.04
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest New Drugs (2011) 0.95
Psychological adjustment of men with prostate cancer: a review of the literature. Biopsychosoc Med (2007) 0.94
Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol (2015) 0.94
Prostate cancer management: 2. An update on locally advanced and metastatic disease. Postgrad Med J (2003) 0.92
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging (2006) 0.86
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Jpn J Clin Oncol (2014) 0.85
Glucocorticoids and prostate cancer treatment: friend or foe? Asian J Androl (2014) 0.83
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. Br J Cancer (2004) 0.83
A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life. World J Urol (2003) 0.82
Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag (2014) 0.80
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer (2016) 0.79
Metastatic castration-resistant prostate cancer: critical review of enzalutamide. Clin Med Insights Oncol (2013) 0.78
Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. Nat Rev Urol (2015) 0.77
End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review. World J Methodol (2014) 0.75
Circulating tumor cells in patients with metastatic castration resistant prostate cancer: exploratory findings at a tertiary referral hospital. Res Rep Urol (2014) 0.75
[Corticosteroids in the management of advanced prostate cancer]. Urologe A (2016) 0.75
[Glucocorticoids and androgens for treatment of tiredness and weakness in palliative care patients : a systematic review]. Schmerz (2012) 0.75
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med (1997) 8.72
Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol (1998) 5.15
Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med (2001) 4.72
Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst (1996) 4.22
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet (2005) 3.77
Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis (1999) 3.39
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol (2005) 2.31
How to avoid false-negative dynamic sentinel node procedures in penile carcinoma. J Urol (2004) 2.29
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol (1997) 2.23
Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl (2000) 2.23
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 2.04
Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery. Br J Surg (2009) 2.00
Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol (2012) 1.96
An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect (1998) 1.82
The clinical meaning of Rankin 'handicap' grades after stroke. Stroke (1995) 1.81
Developing and evaluating cross-cultural instruments from minimum requirements to optimal models. Qual Life Res (1993) 1.78
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer (2005) 1.75
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol (2011) 1.73
The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer (1990) 1.69
Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol (2006) 1.67
Critical appraisal of the PADUA classification and assessment of the R.E.N.A.L. nephrometry score in patients undergoing partial nephrectomy. J Urol (2011) 1.64
An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis (1998) 1.63
The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol (1996) 1.63
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60
Primary aortoenteric fistula: report of eight new cases and review of the literature. Ann Vasc Surg (1996) 1.58
The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer (1995) 1.56
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol (2000) 1.53
Sequential treatment for recurrent localized prostate cancer. J Surg Oncol (2008) 1.45
Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. J Urol (2008) 1.45
Focal therapy in prostate cancer-report from a consensus panel. J Endourol (2010) 1.43
[Prophylactic cranial irradiation in patients with extensive disease caused by small-cell lung cancer responsive to chemotherapy: fewer symptomatic brain metastases and improved survival]. Ned Tijdschr Geneeskd (2008) 1.43
[Incidence and treatment of prostatic carcinoma in the region of the Comprehensive Cancer Center Amsterdam, 1989-1994]. Ned Tijdschr Geneeskd (1996) 1.40
[Clinical reasoning and decision making in practice. A depressive foreign woman with symptoms of malaise]. Ned Tijdschr Geneeskd (2004) 1.39
[Schistosomiasis after swimming in the lake of Malawi]. Ned Tijdschr Geneeskd (1995) 1.38
[Internal radiotherapy in prostatic carcinoma; disappointing long-term results of retropubic Iodine-125 implantation]. Ned Tijdschr Geneeskd (1996) 1.38
Zinc supplementation increases growth and circulating insulin-like growth factor I (IGF-I) in growth-retarded Vietnamese children. Am J Clin Nutr (1996) 1.36
[Less mutilating treatment of penile carcinoma]. Ned Tijdschr Geneeskd (2005) 1.35
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology (2005) 1.34
Carcinoembryonic antigen in the urine of patients with urothelial carcinoma. Br Med J (1972) 1.34
Leptospirosis in Wild Animals in Eastern Canada With Particular Attention to the Disease in Rats. Can J Comp Med Vet Sci (1961) 1.32
Differing interpretations by pathologists of the pT category and grade of transitional cell cancer of the bladder. Br J Urol (1988) 1.30
Caregiver burden in HIV-positive and HIV-negative partners of men with AIDS. J Consult Clin Psychol (1994) 1.27
Differences between gay men in primary relationships and single men: implications for prevention. AIDS Educ Prev (1996) 1.26
Viruses of the California encephalitis complex in indicator rabbits. Am J Trop Med Hyg (1966) 1.25
Measuring quality of life in stroke. Stroke (1993) 1.24
Upper urinary tract cancer: location is correlated with prognosis. Eur Urol (2005) 1.24
Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol (2001) 1.23
A trial of consent procedures for future research with clinically derived biological samples. Br J Cancer (2009) 1.22
Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol (1999) 1.22
Diclofenac sodium versus pethidine in acute renal colic. Br Med J (Clin Res Ed) (1986) 1.22
Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer (2003) 1.22
EAU Guidelines on Penile Cancer. Eur Urol (2004) 1.19
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol (2009) 1.19
Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys (1999) 1.18
Immunosuppression with polyunsaturated fatty acids in renal transplantation. Transplantation (1977) 1.18
Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. J Urol (2005) 1.18
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question? Eur J Cancer (2012) 1.17
Nerve and seminal sparing radical cystectomy with orthotopic urinary diversion for select patients with superficial bladder cancer: an innovative surgical approach. J Urol (2001) 1.16
Sarcomatoid squamous cell carcinoma of the penis: a clinical and pathological study of 5 cases. J Urol (2004) 1.16
Morbidity of dynamic sentinel node biopsy in penile carcinoma. J Urol (2005) 1.15
A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol (2008) 1.14
Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol (1999) 1.14
Quality control of radical prostatectomy: a feasibility study. Eur J Cancer (2001) 1.13
Coping and mood during aids-related caregiving and bereavement. Ann Behav Med (1996) 1.12
Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review. Ann Oncol (2010) 1.12
Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann Oncol (1994) 1.10
Quality of life evaluation in oncological clinical trials - the EORTC model. The EORTC Quality of Life Study Group. Eur J Cancer (2000) 1.10
Use of item response theory to develop a shortened version of the EORTC QLQ-C30 emotional functioning scale. Qual Life Res (2004) 1.10
Determinants of patient satisfaction in oncology settings from European and Asian countries: preliminary results based on the EORTC IN-PATSAT32 questionnaire. Eur J Cancer (2006) 1.10
Are bisexually identified men in San Francisco a common vector for spreading HIV infection to women? Am J Public Health (1994) 1.09
A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol (1998) 1.08
The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys (1999) 1.08
[Iodine-125 implantation in localized cancer of the prostate; too early for rejoicing]. Ned Tijdschr Geneeskd (1998) 1.07
Postbereavement depressive mood and its prebereavement predictors in HIV+ and HIV- gay men. J Pers Soc Psychol (1996) 1.07
[The course of prostatic carcinoma]. Ned Tijdschr Geneeskd (1995) 1.07
Effects of hyperthermia on bladder cancer. Br Med J (1974) 1.05
A carbon dioxide surgical laser. Ann R Coll Surg Engl (1971) 1.05
Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol (2001) 1.05
Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22. Br J Cancer (1994) 1.04
Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res (1989) 1.04
Carcinoembryonic antigen and urothelial carcinoma. Br J Urol (1973) 1.03
The persistence of bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer. Br J Urol (1995) 1.02
Epidemiology of human papillomavirus infection. Scand J Urol Nephrol Suppl (2000) 1.01
Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol (2000) 1.01
Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. Eur Urol (1996) 1.01
Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br J Cancer (2005) 0.99